Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (15793)	2/24/1998 3:35:00 PM
From: celeryroot.com	Read Replies (2) \| Respond to of 32384

Peter, does it really matter what it is used for? I assume what counts is whose brand name is stamped on it. It would be impossible to know what each and every DR. is prescribing for. If Lilly sales people sell it and it is used off label I assume the royalties are paid based on the agreement for its primary use.

To: Peter Singleton who wrote (15793)	2/24/1998 5:29:00 PM
From: David L. Hachey	Read Replies (5) \| Respond to of 32384

Peter; Actually, it's a relatively simple marketing problem to have a single drug formulated in two (or more) vehicles. For example, a topical Targretin ointment could be used for Kaposi's sarcoma; it would be virtually useless for metabolic diseases like diabetes. Oral formulations could be made for breast cancer at a higher dose than indicated for diabetes, although this is a sticky problem if the doses are similar. Simply releasing them under different tradenames would also work. Most oncologists won't prescribe for diabetes, and conversely, endocrinologists won't likley treat cancer. No one has raised the issue of targretin use as a chemoprotective agent to supress the induction of breast cancer. Because of the way these drugs work to cure breast cancer, there is potentially a much wider indicated market in cancer prevention but at a lower dose. From what I can tell, targretin has remarkably few side effects. I wouldn't be surprised if the rat studies for such an indication aren't already in progress. Henry, care to comment. Regards, ...Dave Hachey